These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25516420)

  • 1. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine.
    Mender I; Gryaznov S; Dikmen ZG; Wright WE; Shay JW
    Cancer Discov; 2015 Jan; 5(1):82-95. PubMed ID: 25516420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors.
    Sengupta S; Sobo M; Lee K; Senthil Kumar S; White AR; Mender I; Fuller C; Chow LML; Fouladi M; Shay JW; Drissi R
    Mol Cancer Ther; 2018 Jul; 17(7):1504-1514. PubMed ID: 29654065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells.
    Mender I; Gryaznov S; Shay JW
    Oncoscience; 2015; 2(8):693-5. PubMed ID: 26425659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity.
    Mender I; Zhang A; Ren Z; Han C; Deng Y; Siteni S; Li H; Zhu J; Vemula A; Shay JW; Fu YX
    Cancer Cell; 2020 Sep; 38(3):400-411.e6. PubMed ID: 32619407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
    Zhang G; Wu LW; Mender I; Barzily-Rokni M; Hammond MR; Ope O; Cheng C; Vasilopoulos T; Randell S; Sadek N; Beroard A; Xiao M; Tian T; Tan J; Saeed U; Sugarman E; Krepler C; Brafford P; Sproesser K; Murugan S; Somasundaram R; Garman B; Wubbenhorst B; Woo J; Yin X; Liu Q; Frederick DT; Miao B; Xu W; Karakousis GC; Xu X; Schuchter LM; Mitchell TC; Kwong LN; Amaravadi RK; Lu Y; Boland GM; Wei Z; Nathanson K; Herbig U; Mills GB; Flaherty KT; Herlyn M; Shay JW
    Clin Cancer Res; 2018 Oct; 24(19):4771-4784. PubMed ID: 29563139
    [No Abstract]   [Full Text] [Related]  

  • 6. Turning telomerase into a Jekyll and Hyde case?
    Wellinger RJ
    Cancer Discov; 2015 Jan; 5(1):19-21. PubMed ID: 25583799
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mender I; Batten K; Peyton M; Vemula A; Cornelius C; Girard L; Gao B; Minna JD; Shay JW
    Cancer Res; 2020 Mar; 80(5):929-936. PubMed ID: 31948943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short and dysfunctional telomeres protect from allergen-induced airway inflammation.
    Piñeiro-Hermida S; Martínez P; Blasco MA
    Aging Cell; 2021 May; 20(5):e13352. PubMed ID: 33942458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner.
    Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD
    Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
    Mender I; LaRanger R; Luitel K; Peyton M; Girard L; Lai TP; Batten K; Cornelius C; Dalvi MP; Ramirez M; Du W; Wu LF; Altschuler SJ; Brekken R; Martinez ED; Minna JD; Wright WE; Shay JW
    Neoplasia; 2018 Aug; 20(8):826-837. PubMed ID: 30015158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
    Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
    Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer.
    Eglenen-Polat B; Kowash RR; Huang HC; Siteni S; Zhu M; Chen K; Bender ME; Mender I; Stastny V; Drapkin BJ; Raj P; Minna JD; Xu L; Shay JW; Akbay EA
    Nat Commun; 2024 Jan; 15(1):672. PubMed ID: 38253555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In perspective: An update on telomere targeting in cancer.
    Sugarman ET; Zhang G; Shay JW
    Mol Carcinog; 2019 Sep; 58(9):1581-1588. PubMed ID: 31062416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
    Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
    Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Super-telomeres in transformed human fibroblasts.
    Chiodi I; Belgiovine C; Zongaro S; Ricotti R; Horard B; Lossani A; Focher F; Gilson E; Giulotto E; Mondello C
    Biochim Biophys Acta; 2013 Aug; 1833(8):1885-93. PubMed ID: 23570868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRD4 inhibitors block telomere elongation.
    Wang S; Pike AM; Lee SS; Strong MA; Connelly CJ; Greider CW
    Nucleic Acids Res; 2017 Aug; 45(14):8403-8410. PubMed ID: 28854735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of U-STELA for Accurate Measurement of Extremely Short Telomeres.
    Serakinci N; Cagsin H; Mavis M
    Methods Mol Biol; 2019; 2045():217-224. PubMed ID: 29542055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
    Babizhayev MA; Yegorov YE
    J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.
    Fischer-Mertens J; Otte F; Roderwieser A; Rosswog C; Kahlert Y; Werr L; Hellmann AM; Berding M; Chiu B; Bartenhagen C; Fischer M
    Cell Oncol (Dordr); 2022 Oct; 45(5):991-1003. PubMed ID: 35953764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells.
    Saretzki G; Ludwig A; von Zglinicki T; Runnebaum IB
    Cancer Gene Ther; 2001 Oct; 8(10):827-34. PubMed ID: 11687906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.